ZA200610667B - 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors - Google Patents
3-Aminocyclopentanecarboxamides as modulators of chemokine receptors Download PDFInfo
- Publication number
- ZA200610667B ZA200610667B ZA200610667A ZA200610667A ZA200610667B ZA 200610667 B ZA200610667 B ZA 200610667B ZA 200610667 A ZA200610667 A ZA 200610667A ZA 200610667 A ZA200610667 A ZA 200610667A ZA 200610667 B ZA200610667 B ZA 200610667B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- pyran
- amine
- compound
- trifluoromethyl
- Prior art date
Links
- 102000009410 Chemokine receptor Human genes 0.000 title claims description 20
- 108050000299 Chemokine receptor Proteins 0.000 title claims description 20
- OLHSXPNNEJJDLQ-UHFFFAOYSA-N 3-aminocyclopentane-1-carboxamide Chemical class NC1CCC(C(N)=O)C1 OLHSXPNNEJJDLQ-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 133
- 150000001875 compounds Chemical class 0.000 claims description 90
- -1 carbocyclyloxy Chemical group 0.000 claims description 71
- 125000003545 alkoxy group Chemical group 0.000 claims description 58
- 125000001188 haloalkyl group Chemical group 0.000 claims description 51
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 44
- 125000000623 heterocyclic group Chemical group 0.000 claims description 41
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 27
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 125000000304 alkynyl group Chemical group 0.000 claims description 23
- 125000003342 alkenyl group Chemical group 0.000 claims description 22
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 16
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 12
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 12
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229940002612 prodrug Drugs 0.000 claims description 11
- 239000000651 prodrug Substances 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 7
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 14
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 claims 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 229940124639 Selective inhibitor Drugs 0.000 claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- BNBYKPINYCJXDS-HBNDIDGLSA-N [(1s,3r)-1-ethyl-3-[[(4r)-3-methyloxan-4-yl]amino]cyclopentyl]-[4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]methanone Chemical compound N([C@@H]1CC[C@](C1)(CC)C(=O)N1CCN(CC1)C=1N=C(C=CN=1)C(F)(F)F)[C@@H]1CCOCC1C BNBYKPINYCJXDS-HBNDIDGLSA-N 0.000 claims 1
- COAGXLRRWYBTCD-VVQFGVONSA-N [(1s,3r)-1-methyl-3-[[(4r)-3-methyloxan-4-yl]amino]cyclopentyl]-[4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]methanone Chemical compound CC1COCC[C@H]1N[C@H]1C[C@@](C)(C(=O)N2CCN(CC2)C=2N=C(C=CN=2)C(F)(F)F)CC1 COAGXLRRWYBTCD-VVQFGVONSA-N 0.000 claims 1
- XXFXDJVYSVERAI-NOZRDPDXSA-N [(1s,3r)-3-(oxan-4-ylamino)-1-propan-2-ylcyclopentyl]-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)methanone Chemical compound N([C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CC=C(CC1)C=1C=CC=CC=1)C1CCOCC1 XXFXDJVYSVERAI-NOZRDPDXSA-N 0.000 claims 1
- QPEPWXAREJQKIR-NOZRDPDXSA-N [(1s,3r)-3-(oxan-4-ylamino)-1-propan-2-ylcyclopentyl]-(4-phenylpiperidin-1-yl)methanone Chemical compound N([C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCC(CC1)C=1C=CC=CC=1)C1CCOCC1 QPEPWXAREJQKIR-NOZRDPDXSA-N 0.000 claims 1
- DNPRHSLKGYTIJX-LEOFDFDVSA-N [(1s,3r)-3-[(3-ethyloxan-4-yl)amino]-1-propan-2-ylcyclopentyl]-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methanone Chemical compound CCC1COCCC1N[C@H]1C[C@](C(=O)N2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)(C(C)C)CC1 DNPRHSLKGYTIJX-LEOFDFDVSA-N 0.000 claims 1
- FRYVYNNKNQWDFO-WNGXIMJUSA-N [(1s,3r)-3-[(3-methyloxan-4-yl)amino]-1-propan-2-ylcyclopentyl]-[4-[6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]methanone Chemical compound N([C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCN(CC1)C=1N=CN=C(C=1)C(F)(F)F)C1CCOCC1C FRYVYNNKNQWDFO-WNGXIMJUSA-N 0.000 claims 1
- IYAPLQFFXFUGCM-HSFGIDRPSA-N [(1s,3r)-3-[[(4r)-3-methyloxan-4-yl]amino]-1-[(3r)-oxolan-3-yl]cyclopentyl]-[4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]methanone Chemical compound CC1COCC[C@H]1N[C@H]1C[C@](C(=O)N2CCN(CC2)C=2N=C(C=CN=2)C(F)(F)F)([C@@H]2COCC2)CC1 IYAPLQFFXFUGCM-HSFGIDRPSA-N 0.000 claims 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 17
- 102000019034 Chemokines Human genes 0.000 description 13
- 108010012236 Chemokines Proteins 0.000 description 13
- 208000031886 HIV Infections Diseases 0.000 description 12
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 150000004885 piperazines Chemical class 0.000 description 8
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 7
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 7
- ZGDKVKUWTCGYOA-URGPHPNLSA-N [4-[4-[(z)-c-(4-bromophenyl)-n-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone Chemical compound C=1C=C(Br)C=CC=1C(=N/OCC)\C(CC1)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)C=C[N+]([O-])=C1C ZGDKVKUWTCGYOA-URGPHPNLSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- AYXBAIULRDEVAS-UHFFFAOYSA-N dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium;iodide Chemical compound [I-].C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 AYXBAIULRDEVAS-UHFFFAOYSA-N 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 125000002346 iodo group Chemical group I* 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 230000007502 viral entry Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 239000002975 chemoattractant Substances 0.000 description 3
- 230000003399 chemotactic effect Effects 0.000 description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 2
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000011652 Formyl peptide receptors Human genes 0.000 description 2
- 108010076288 Formyl peptide receptors Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 206010027260 Meningitis viral Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000008424 iodobenzenes Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
- 125000005482 norpinyl group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 201000010044 viral meningitis Diseases 0.000 description 2
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- BSVHTRRLCAVQCZ-JDEXMCKMSA-N (2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]pyrro Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 BSVHTRRLCAVQCZ-JDEXMCKMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- QCZZSANNLWPGEA-UHFFFAOYSA-N 1-(4-phenylphenyl)ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC=CC=C1 QCZZSANNLWPGEA-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004562 2,3-dihydroindol-1-yl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical class FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-UHFFFAOYSA-N 2-amino-2-phenylethanol Chemical compound OCC(N)C1=CC=CC=C1 IJXJGQCXFSSHNL-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- 150000005762 2-bromopyridine Chemical class 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical class ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- SOSPMXMEOFGPIM-UHFFFAOYSA-N 3,5-dibromopyridine Chemical compound BrC1=CN=CC(Br)=C1 SOSPMXMEOFGPIM-UHFFFAOYSA-N 0.000 description 1
- AOOZLVWDZUPEHT-UHFFFAOYSA-N 3-bromo-5-iodopyridine Chemical compound BrC1=CN=CC(I)=C1 AOOZLVWDZUPEHT-UHFFFAOYSA-N 0.000 description 1
- ROFNJLCLYMMXCT-UHFFFAOYSA-N 4-aminohexanoic acid Chemical class CCC(N)CCC(O)=O ROFNJLCLYMMXCT-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 1
- 108050005711 C Chemokine Proteins 0.000 description 1
- 102000017483 C chemokine Human genes 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 108091008927 CC chemokine receptors Proteins 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 102000005674 CCR Receptors Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108091008928 CXC chemokine receptors Proteins 0.000 description 1
- 102000054900 CXCR Receptors Human genes 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 1
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 101000978374 Mus musculus C-C motif chemokine 12 Proteins 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 108010077495 Peptide oostatic hormone Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 235000014548 Rubus moluccanus Nutrition 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical class OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000797 effect on infection Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000006138 lithiation reaction Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
- 229940073569 n-methylephedrine Drugs 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005893 naphthalimidyl group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N phenyl bromide Natural products BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000003567 signal transduction assay Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000004089 sulfido group Chemical group [S-]* 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF
CHEMOKINE RECEPTORS
The present invention relates to compounds that modulate the activity of chemokine receptors such as CCR2. In some embodiments, the compounds are selective for CCR2. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and cancer.
The migration and transport of leukocytes from blood vessels into diseased tissues is involved in the initiation of normal disease-fighting inflammatory responses. The process, also known as leukocyte recruitment, is also related to the onset and progression of inflammatory and autoimmune diseases. The resulting pathology of these diseases derives from the attack of the body's immune system defenses on apparently normal tissues.
Accordingly, preventing and blocking leukocyte recruitment to target tissues in inflammatory disease, metabolic disease, autoimmune disease and cancer would be a highly effective approach to therapeutic intervention.
The different classes of leukocyte cells that are involved in cellular immune responses include monocytes, lymphocytes, neutrophils, eosinophils, natural killer cells, mast cells and basophils. In most cases, monocytes and lymphocytes are the leukocyte classes that initiate, coordinate, and maintain chronic inflammatory responses, and blockage of these cells from entering inflammatory sites is desirable. Lymphocytes attract monocytes to the tissue sites, which, collectively with lymphocytes, are responsible for most of the actual tissue damage that occurs in inflammatory disease. Infiltration of the lymphocytes and/or monocytes is known to lead to a wide range of chronic, autoimmune diseases, and also organ transplant rejection. These diseases include, but are not limited to, rheumatoid arthritis, chronic contact dermatitis, asthma, hyperallergic conditions, inflammatory bowel disease, lupus, systemic lupus erythematosus, multiple sclerosis, atherosclerosis, psoriasis, sarcoidosis, idiopathic pulmonary fibrosis, dermatomyositis, skin pemphigoid and related diseases, (e.g., Pemphigus vulgaris, P. foliacious, P. erythematosis), glomerulonephritides, vasculitides, hepatitis, diabetes, allograft rejection, and graft-versus-host disease.
The process by which leukocytes leave the bloodstream, accumulate at inflammatory sites, and start disease is believed to have at least three steps which have been described as (1) rolling, (2) activation/firm adhesion and (3) transendothelial migration [Springer, T. A.,
Nature 346:425-433 (1990); Lawrence and Springer, Cell 65:859-873 (1991); Butcher, E. C.,
Cell 67:1033-1036 (1991)]. The second step is mediated at the molecular level by chemoattractant receptors. Chemoattractant receptors on the surface of leukocytes bind chemoattractant cytokines which are secreted by cells at the site of apparent damage or infection. Receptor binding activates leukocytes, increases the adhesiveness of the adhesion molecules that mediate transendothelial migration, and promotes directed migration of the cells toward the source of the chemoattractant cytokine.
Chemotactic cytokines (leukocyte chemoattractant/activating factors) also known as chemokines, also known as intercrines and SIS cytokines, are a group of inflammatory/ immunomodulatory polypeptide factors of molecular weight 6-15 kDa that are released by a wide variety of cells such as macrophages, monocytes, eosinophils, neutrophils, fibroblasts, vascular endotherial cells, epithelial cells, smooth muscle cells, and mast cells, at inflammatory sites (reviewed in Luster, New Eng. J Med., 338, 436-445 (1998) and Rollins,
Blood, 90, 909-928 (1997)). Also, chemokines have been described in Oppenheim, J. J. et al.,
Annu. Rev. Immunol., 9:617-648 (1991); Schall and Bacon, Curr. Opin. Immunol., 6:865- 873 (1994); Baggiolini, M., et al., and Adv. Immunol., 55:97-179 (1994). Chemokines have the ability to stimulate directed cell migration, a process known as chemotaxis. Chemokines can be grouped into two major subfamilies, based on whether the two amino terminal cysteine residues are immediately adjacent (CC family) or separated by one amino acid (CXC family). These differences correlate with the organization of the two subfamilies into separate gene clusters. Within each gene cluster, the chemokines typically show sequence similarities between 25 to 60%. The CXC chemokines, such as interleukin-8 (IL-8), neutrophil-activating protein-2 (NAP-2) and melanoma growth stimulatory activity protein (MGSA) are chemotactic primarily for neutrophils and T lymphocytes, whereas the CC chemokines, such as RANTES, MIP-1a, MIP-1, the monocyte chemotactic proteins (MCP-1, MCP-2, MCP-3,
MCP-4, and MCP-5) and the eotaxins (-1 and -2) are chemotactic for, among other cell types, macrophages, T lymphocytes, eosinophils, dendritic cells, and basophils. There also exist the chemokines lymphotactin-1, lymphotactin-2 (both C chemokines), and fractalkine (a
CXXXC chemokine) that do not fall into either of the major chemokine subfamilies.
MCP-1 (also known as MCAF (abbreviation for macrophage chemotactic and activating factor) or JE) is a CC chemokine produced by monocytes/macrophages, smooth muscle cells, fibroblasts, and vascular endothelial cells and causes cell migration and cell adhesion of monocytes (see for example Valente, A. J, et al., Biochemistry, 1988, 27, 4162;
Matsushima, K., et al., J. Exp. Med., 1989, 169, 1485; Yoshimura, T., et al, J. Immunol, 1989, 142, 1956; Rollins, B. J., et al., Proc. Natl. Acad. Sci. USA, 1988, 85, 3738; Rollins, B.
J, etal, Blood, 1991, 78, 1112; Jiang, Y., et al., J. Immunol., 1992, 148, 2423; Vaddi, K., et al, J. Immunol., 1994, 153, 4721), memory T lymphocytes (see for example Carr, M. W_, et al., Proc. Natl. Acad. Sci. USA, 1994, 91, 3652), T lymphocytes (see for example Loetscher,
Petal, FASEB J ., 1994, 8, 1055) and natural killer cells (see for example Loetscher, P., et al., J. Immunol., 1996, 156, 322; Allavena, P., et al, Eur. J. Immunol. , 1994, 24, 3233), as well as mediating histamine release by basophils (see for example Alam, R., et al., J. Clin.
Invest, 1992, 89, 723; Bischoff, S. C., et al,, J. Exp. Med., 1992, 175, 1271; Kuna, P., et al.,
J. Exp. Med, 1992, 175, 489). In addition, high expression of MCP-1 has been reported in diseases where accumulation of monocyte/macrophage and/or T cells is thought to be important in the initiation or progression of diseases, such as atherosclerosis (see for example
Hayes, 1. M.,, et al., Arterioscler. Thromb. Vasc. Biol., 1998, 18, 397; Takeya, M.. et al.,
Hum. Pathol, 1993, 24, 534; Yla-Herttuala, S., et al., Proc. Natl. Acad. Sci. USA, 1991, 88, 5252; Nelken, N. A., J. Clin. Invest., 1991, 88, 1121), rheumatoid arthritis (see for example
Koch, A. E., et al, J. Clin, Invest., 1992, 90, 772; Akahoshi, T., et al., Arthritis Rheum., 1993, 36, 762; Robinson, E., et al.,, Clin. Exp. Immunol., 101, 398), nephritis (see for example Noris, M., et al., Lab. Invest., 1995, 73, 804; Wada, T., at al., Kidney Int., 1996, 49, 761; Gesualdo, L., et al., Kidney Int., 1997, 51, 155), nephropathy (see for example Saitoh,
A. etal, J. Clin. Lab. Anal., 1998, 12, 1; Yokoyama, H., et al., J. Leukoc. Biol., 1998, 63, 493), pulmonary fibrosis, pulmonary sarcoidosis (see for example Sugiyama, Y., et al.,
Internal Medicine, 1997, 36, 856), asthma (see for example Karina, M., et al., J. Invest.
Allergol. Clin. Immunol., 1997, 7, 254; Stephene, T. H., Am. J. Respir. Crit. Care Med., 1997, 156, 1377; Sousa, A. R., et al., Am. J. Respir. Cell Mol. Biol., 1994, 10, 142), multiple sclerosis (see for example McManus, C., et al., J. Neuroimmunol., 1998, 86, 20), psoriasis (see for example Gillitzer, R., et al., J. Invest. Dermatol., 1993, 101, 127), inflammatory bowel disease (see for example Grimm, M. C., et al, J. Leukoc. Biol, 1996, 59, 804;
Reinecker, H. C., et al., Gastroenterology, 1995, 106, 40), myocarditis (see for example
Seino, Y., et al., Cytokine, 1995, 7, 301), endometriosis (see for example Jolicoeur, C., et al.,
Am. J. Pathol, 1998, 152, 125), intraperitoneal adhesion (see for example Zeyneloglu, H. B., et al, Human Reproduction, 1998, 13, 1194), congestive heart failure (see for example
Aurust, P., et al, Circulation, 1998, 97, 1136), chronic liver disease (see for example Marra,
F. etal, Am. J. Pathol., 1998, 152, 423), viral meningitis (see for example Lahstz, F. etal,
Eur. J. Immunol., 1997, 27, 2484), Kawasaki disease (see for example Wong, M.; et al, J.
Rheumatol., 1997, 24,1179) and sepsis (see for example Salkowski, C. A.; et al., Infect.
Immun., 1998, 66, 3569). Furthermore, anti-MCP-1 antibody has been reported to show an inhibitory effect or a therapeutic effect in animal models of rheumatoid arthritis (see for example Schimmer, R. C., et al., J. Inmunol., 1998, 160, 1466; Schrier, D. J, J. Leukoc.
Biol., 1998, 63, 359; Ogata, H., ¢t al, J. Pathol., 1997, 182, 106), multiple sclerosis (see for example Karpus, W. J., et al, J. Leukoc. Biol, 1997, 62, 681), nephritis (see for example
Lloyd, C. M., et al, J. Exp. Med., 1997, 185, 1371; Wada, T., et al, FASEB J., 1996, 10, 1418), asthma (see for example Gonzalo, J.-A. et al., J. Exp. Med., 1998, 188, 157; Lukacs,
N. W., J. Immunol., 1997, 158, 4398), atherosclerosis (see for example Guzman, L. A, et al,
Circulation, 1993, 88 (suppl.), I-371), delayed type hypersensitivity (see for example Rand,
M. L., et al, Am. J. Pathol., 1996, 148, 855), pulmonary hypertension (see for example
Kimura, H., et al., Lab. Invest., 1998, 78, 571), and intraperitoneal adhesion (see for example
Zeynelogly, H. B., et al, Am. J. Obstet. Gynecol., 1998, 179, 438). A peptide antagonist of MCP-1, MCP-1(9-76), has been also reported to inhibit arthritis in the mouse model (see
Gong, J.-H., J. Exp. ,4ed. , 1997, 186, 131), as well as studies in MCP-1-deficient mice have shown that MCP-1 is essential for monocyte recruitment in vivo (see Lu, B., et al., J. Exp.
Med., 1998, 187, 601; Gu, L., et al., Moll. Cell, 1998, 2, 275).
Chronic obstructive pulmonary disease (COPD) ranks among the most common causes of death in Western societies. It is defined by a progressive decline in lung function, only partly reversible by bronchodilator drugs. COPD is characterized by chronic inflammation in the airways or alveoli that differs from that seen in asthma, involving increased numbers of neutrophils, macrophages, CD8+ T cells, and/or mast cells in the airway walls, alveolar compartments, and vascular smooth muscle. Cytokines associated with COPD are believed to include tumor necrosis factor (TNF)-alpha, interferon (TFN)- gamma, interleukin (IL)-1 beta, IL-6, IL-8 and MCP-1. CCR2 is known to be a receptor for
MCP-1, and recent data support a role for MCP-1 and CCR2 in airway remodeling and inflammation directly or via macrophages. Thus, antagonists of CCR2 are an attractive approach to therapeutic treatment of COPD (De Boer, W. I., Chest, 2002, 121, 2095-2185).
The literature indicates that chemokines such as MCP-1 and MIP-la attract monocytes and lymphocytes to disease sites and mediate their activation and thus are thought to be intimately involved in the initiation, progression and maintenance of diseases deeply involving monocytes and lymphocytes, such as atherosclerosis, diabetes, restenosis, rheumatoid arthritis, psoriasis, asthma, ulcerative colitis, nephritis (nephropathy), multiple sclerosis, pulmonary fibrosis, myocarditis, hepatitis, pancreatitis, sarcoidosis, Crohn's disease, endometriosis, congestive heart failure, viral meningitis, cerebral infarction, neuropathy, Kawasaki disease, and sepsis (see for example Rovin, B. H, et al, Am. J.
Kidney. Dis., 1998, 31, 1065; Lloyd, C., et al, Curr. Opin. Nephrol. Hypertens., 1998, 7, 281;
Conti, P., et al., Allergy and Asthma Proc., 1998, 19, 121; Ransohoff, R. M,, et al., Trends
Neurosci., 1998, 21, 154; MacDermott, R. P., et al., Inflammatory Bowel Diseases, 1998, 4, 54).
The chemokines bind to specific cell-surface receptors belonging to the family of G- protein-coupled seven-transmembrane-domain proteins (reviewed in Horuk, Trends Pharm.
Sci, 15, 159-165 (1994)) which are termed "chemokine receptors." On binding their cognate ligands, chemokine receptors transduce an intracellular signal through the associated trimeric
G proteins, resulting in, among other responses, a rapid increase in intracellular calcium concentration, changes in cell shape, increased expression of cellular adhesion molecules, degranulation, and promotion of cell migration.
Genes encoding receptors of specific chemokines have been cloned, and it is known that these receptors are G protein-coupled seven-transmembrane receptors present on various leukocyte populations. So far, at least six CXC chemokine receptors (CXCR1-CXCR6} and nine CC chemokine receptors (CCR1-CCR8 and CCR10) have been identified. For example
IL-8 is a ligand for CXCR! and CXCR2, MIP-1a: is a ligand for CCR1 and CCR5, and MCP- 1 is a ligand for CCR2A and CCR2B (for reference, see for example, Holmes, W. E., et al.,
Science 1991, 253, 1278-1280; Murphy P. M., et al., Science, 253, 1280-1283; Neote, K. et al, Cell, 1993, 72, 415-425; Charo, I. F., et al., Proc. Natl. Acad. Sci. USA, 1994, 91, 2752- 2756; Yamagami, S., et al, Biochem. Biophys. Res. Commun., 1994, 202, 1156-1162;
Combadier, C., et al., The Journal of Biological Chemistry, 1995, 270, 16491-16494, Power,
C. A, etal, J. Biol. Chem., 1995, 270, 19495-19500; Samson, M., et al., Biochemistry, 1996, 35, 3362-3367; Murphy, P. M., Annual Review of Immunology, 1994, 12, 592-633). It has been reported that lung inflammation and granuroma formation are suppressed in CCR1- deficient mice (see Gao, J.-L., et al., J. Exp. Med., 1997, 185, 1959; Gerard, C., et al., J. Clin.
Invest, 1997, 100, 2022), and that recruitment of macrophages and formation of atherosclerotic lesion decreased in CCR2-deficient mice (see Boring, L., et al., Nature, 1998, 394, 894; Kuziel, W. A., et al., Proc. Natl. Acad. Sci., USA, 1997, 94, 12053; Kurihara, T., et al,, J. Exp. Med., 1997, 186, 1757; Boring, L., et al., J. Clin. Invest., 1997, 100, 2552).
Chemokine receptors are also known as coreceptors for viral entry leading to viral infection such as, for example, HIV infection. Reverse transcription and protein processing are the classic steps of the viral life cycle which antiretroviral therapeutic agents are designed to block. Although many new drugs that are believed to block viral entry hold promise, there is currently no agent to which HIV-1 has not been able to acquire resistance. Multiple rounds of viral replication are required to generate the genetic diversity that forms the basis of resistance. Combination therapy in which replication is maximally suppressed remains a cornerstone of treatment with entry inhibitors, as with other agents. The targeting of multiple steps within the viral entry process is believed to have the potential for synergy (Starr-Spires et al., Clin. Lab. Med., 2002, 22(3), 681.)
HIV-1 entry into CD4(+) cells requires the sequential interactions of the viral envelope glycoproteins with CD4 and a coreceptor such as the chemokine receptors CCRS and CXCR4. A plausible approach to blocking this process is to use small molecule antagonists of coreceptor function. The TAK-779 molecule is one such antagonist of CCRS that acts to prevent HIV-1 infection. TAK-779 inhibits HIV-1 replication at the membrane fusion stage by blocking the interaction of the viral surface glycoprotein gp120 with CCRS.
The binding site for TAK-779 on CCR5 is located near the extracellular surface of the receptor, within a cavity formed between transmembrane helices 1, 2, 3, and 7 (Dragic et al.,
Proc. Natl. Acad. Sci. USA, 2000, 97(10), 5639).
The chemokine receptors CXCR4 and CCRS are believed to be used as co-receptors by the T cell-tropic (X4) and macrophage-tropic (RS) HIV-1 strains, respectively, for entering their host cells. Propagation of RS strains of HIV-1 on CD4 lymphocytes and macrophages requires expression of the CCRS coreceptor on the cell surface. Individuals lacking CCRS (CCRS Delta 32 homozygous genotype) are phenotypically normal and resistant to infection with HIV-1. Viral entry can be inhibited by the natural ligands for
CXCR4 (the CXC chemokine SDF-1) and CCRS (the CC chemokines RANTES, MIP-1alpha and MIP-1beta). The first non-peptidic compound that interacts with CCRS, and not with
CXCRA4, is a quaternary ammonium derivative, called TAK-779, which also has potent but variable anti-HIV activity (De Clercq et al., Antivir. Chem. Chemother. 2001, 12 Suppl. 1, 19.
SCH-C (SCH 351125) is another small molecule inhibitor of HIV-1 entry via the
CCRS coreceptor. SCH-C, an oxime-piperidine compound, is a specific CCRS antagonist as determined in multiple receptor binding and signal transduction assays. This compound specifically inhibits HIV-1 infection mediated by CCRS in U-87 astroglioma cells but has no effect on infection of CXCR4-expressing cells. (Strizki et al, Proc. Natl. Acad. Sci. USA, 2001, 98(22), 12718 or Tremblay et al., Antimicrobial Agents and Chemotherapy, 2002, 46(5), 1336).
ADI101, chemically related to SCH-C, also inhibits the entry of human immunodeficiency virus type 1 (HIV-1) via human CCRS. It has been found that AD101 inhibits HIV-1 entry via rhesus macaque CCRS while SCH-C does not. Among the eight residues that differ between the human and macaque versions of the coreceptor, only one, methionine-198, accounts for the insensitivity of macaque CCRS5 to inhibition by SCH-C.
Position 198 is in CCRS transmembrane (TM) helix S and is not located within the previously defined binding site for AD101 and SCH-C, which involves residues in TM helices 1, 2,3, and 7. Based on studies of amino acid substitutions in CCRS5, it has been suggested that the region of CCRS5 near residue 198 can influence the conformational state of this receptor. (Billick et al,, 2004, J. Virol., 78(8), 4134).
The identification of compounds that modulate the activity of chemokine receptors represents a desirable drug design approach for the needed development of pharmacological agents for the treatment of diseases associated with chemokine receptor activity. The compounds of the present invention help fulfill these and other needs.
The present invention provides compounds of Formula I:
RE
RS
AREY
RY A
I or pharmaceutically acceptable salts or prodrugs thereof, wherein constituent members are provided herein.
The present invention further provides compositions comprising a compound of
Formulaland a pharmaceutically acceptable carrier.
The present invention further provides methods of modulating activity of a chemokine receptor comprising contacting said chemokine receptor with a compound of Formula I.
The present invention further provides methods of treating a disease associated with expression or activity of a chemokine receptor in a patient comprising administering to the patient a therapeutically effective amount of a compound of Formula I.
The present invention further provides a compound described herein for use in therapy.
The present invention further provides a compound described herein for the preparation of a medicament for use in therapy.
Compounds
The present invention provides, infer alia, compounds of Formula I:
RS
R7 o) jo re NY wx ve
R% A
I or pharmaceutically acceptable salt or prodrug thereof, wherein: a dashed line indicates an optional bond;
Wis:
RA ol (en p RM of RET,
Vis N, NO or CR
X is N, NO or CR%;
Y is N, NO or CR?;
Z is N, NO or CR*; wherein no more than one of X,Y and Z is NO;
Ais 0, S, CRR®; or NRF;
R*, RM, R%and R®! are each, independently, H, OH, halo, Cy. alkyl, Cy. alkenyl, Cy. alkynyl, Cy.¢ haloalkyl, Cy.6 alkoxy, Cis haloalkoxy, heterocyclyl, carbocyelyl, NR!’R'2,
NR!°CO,R!; NR®CONRR", NR1°SO,NR"R 2, NR'-S0,-R", CN, CONRUR™2, COR,
NO, SR, SOR", SO;R'%; or SO,-NR*R2,
RC and RP are each, independently, H, OH, halo, Cy alkyl, Cy haloalkyl, Cis alkoxy, Cig haloalkoxy, Cis thioalkoxy, heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylalkyl, carbocyclylalkyl, NRIR2, NRCORY; NR'’CONRYVRY,
NR9SO,NR'R'2, NR'%-80,-R"!, CN, CONR'R"?, CO;R', NO,, SR", SOR", SOR"; or 5S SO,-NR!®R!?, wherein said Cj.¢ alkyl is optionally substituted with 1-5 substituents selected from hydroxyl, OH, Cis alkoxy, and Cc haloalkyl and wherein said heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylalkyl, and carbocyclylalkyl are each optionally substituted with 1-4 substituents selected from Cy. alkyl, Ca alkenyl, Cy. alkynyl, halo, C14 haloalkyl, CN, NO; ORD, SR®, C(O)RY, C(O)OR", C(O)NR"R', NR“R",
NR“CONHR!, NR CORY, NRPC(O)ORY, S(O)R!, S(O)R"“, S(ONRR' or
SO,NRIR!S:
RF is H, OH, Ci alkyl, Ci.¢ haloalkyl, Ci alkoxy, C.¢ haloalkoxy, heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylalkyl, carbocyelylalkyl, SOR, SO,R'; or SO;-
NR'®R'2, wherein said Cy. alkyl is optionally substituted with 1-5 substituents selected from hydroxyl, OH, C,s alkoxy, and Ci. haloalkyl and wherein said heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylalkyl, and carbocyclylalkyl are optionally substituted with 1-4 substituents selected from C,.¢ alkyl, C,¢ alkenyl, Cy¢ alkynyl, halo, C;4 haloalkyl, CN,
NO,, ORY, SR®, CORY, C(O)OR”, CONRPR, NR"RY, NR“CONHRY,
NRPC(O)R™, NR'*C(0)OR", S(O)RY, S(O)R™, S(OINRR'6 or SO,NR’R'S;
R! is Cy alkyl, Cy. haloalkyl, Cy. hydroxyalkyl, -(Cos alkyl)-O-(C1.¢ alkyl), (Cos alkyl)-S-(C1¢ alkyl), «(Cos alkyl)-(Cs5 cycloalkyl)-(Cos alkyl), OH, OR!®, SR", COR"),
COR", CONR'R'2, carbocyclyl, heterocyclyl, CN, NR'’R'?, NR!°SO,R'®, NR'°’COR,
NR COR", NR'’CONR™, CR"R''CO,R" or CR'’R''OCORY;
RZ, R?, R%, R® and R° are each, independently, H, OH, halo, C,.¢ alkyl, C; haloalkyl,
Cis alkoxy, Ci haloalkoxy, Cg thicalkoxy, NR'’R', NR!’CO,RY; NRCONR!®RY,
NRYSO,NR'’R", NRY-SO,-R!, heterocyclyl, carbocyclyl, carbocyelyloxy, heterocyclyloxy, CN, NO,, COR", CONR'R?, CO,R'?, NO,, SRY, SOR!?, SO,R'%; or SO,-
NRIR 12,
R7isHor Ci alkyl optionally substituted by 1-3 substituents selected from halo, OH,
CO:H, CO,-(Cy.s alkyl), or Cy_3 alkoxy;
R® and R¥ are each, independently, H, C;.salkyl, Ci¢ haloalkyl, halo, C,.; alkoxy, C;. 3 haloalkoxy, Cs.¢ cycloalkyl, Ci cycloalkyloxy, OH, CO.R', OCOR'’; wherein said Cis alkyl is optionally substituted with one or more substituents selected from F, C3 alkoxy, OH or COR",
or R7 and R® together form a bridging Cos alkylene or «(Co alkyl)-0-(Cy3 alkyl)- group to form a 5-7 membered ring; or R® and R? together with the carbon atom to which they are attached form a 3-7 membered spirocyclyl group;
R®and RY are each, independently, H, C,.¢ alkyl, halo, Cy.3 alkoxy, C;.; haloalkoxy,
Ci. cycloalkyl, Cs cycloalkyloxy, OH, CORY, OCORY , wherein said Ci alkyl is optionally substituted with one or more substituents selected from F, Ci.3 alkoxy, OH or
COR"; or R? and R® together with the carbon atom to which they are attached form a 3-7 membered spirocyclyl group; or R® and R’® together with the C atoms to which they are attached form a fused 3-7 membered cycloalkyl group or 3-7 membered heterocycloalkyl group;
RY is H, C;¢alkyl, benzyl, phenyl, or Cs. cycloalkyl, wherein said Cy.¢alkyl, benzyl, phenyl, or Cj. cycloalkyl is optionally substituted with 1-3 selected from halo, OH, C;.3 alkyl, Cy.; haloalkyl, C,.; alkoxy, C,.; haloalkoxy, CO.H, and CO-(C).s alkyl);
RY is H, OH, Cs alkyl, C. alkoxy, benzyl, phenyl, benzyloxy, phenyloxy, Cs.s cycloalkyl or Cig cycloalkyloxy, wherein said Ci alkyl, Ci.s alkoxy, benzyl, phenyl, benzyloxy, phenyloxy, Css cycloalkyl or Cs. cycloalkyloxy, is optionally substituted with 1- 3 substituents selected from halo, OH, C,.; alkyl, C,.; alkoxy, CO,H, CO,-(C,.¢ alkyl) and
CFs;
RY is H, Calkyl, benzyl, phenyl, or C3 cycloalkyl, wherein said Cisalkyl, benzyl, phenyl, or Cs cycloalkyl is optionally substituted with 1-3 selected from halo, OH, Ci.3 alkyl, C,.; haloalkyl, C,.; alkoxy, C;.3 haloalkoxy, CO;H, and CO,-(C,¢ alkyl);
RY and R™ are each, independently, H, C, alkyl, C,.¢ haloalkyl, Cp alkenyl, Ca. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl;
RY and R'S are each, independently H, C.¢ alkyl, C,.¢ haloalkyl, C,.¢ alkenyl, Ca. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R¥ and R'® together with the N atom to which they are attached form a 4-6 membered heterocyclyl group; pisOorl; and with the proviso that when A is O and one of R® and R® is H, the other of R®and R¥ is other than C,.3 alkoxy, C,.3 haloalkoxy, Cj cycloalkyloxy or OH.
The present invention further provides, inter alia, compounds of Formula II:
RS
R7 oO jos a | ~ Cw al
RS oe a or pharmaceutically acceptable salts or prodrugs thereof, wherein: a dashed line indicates an optional bond;
Wis:
RA iT
Hh e(- or RM or RB1
X is N, NO or CR;
Y is N, NO or CR;
Z is N, NO or CR*; wherein no more than one of X, Y and Z is NO;
Ais 0, S, CRR”; or NR;
RA, R*, RPand R®! are each, independently, H, OH, halo, Cy. alkyl, Cy alkenyl, C1. alkynyl, C,.¢ haloalkyl, C4 alkoxy, Cj haloalkoxy, heterocyclyl, carbocyclyl, NR!R,
NR'’CO,R!; NR’CONRR?, NR’SO,NR’R"Z, NR!°-50,-R"!, CN, CONR’R"2, CO,RY,
NO», SR!?, SOR, SOR! or SO,-NR'R'2;
R® and RP are each, independently, H, OH, halo, C;¢ alkyl, C,¢ haloalkyl, C;. alkoxy, Cis haloalkoxy, C,¢ thioalkoxy, heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylalkyl, carbocyclylalkyl, NR°R'2, NRPCO,RY; NRCONR'R",
NR'SO,NR'R'?, NR"-S0,-R"!, CN, CONR''R'?, COR’, NO,, SR", SOR, SO,R"; or
SO,-NR!'%R'2, wherein said Cy.¢ alkyl is optionally substituted with 1-5 substituents selected from hydroxyl, OH, C;; alkoxy, and Cj. haloalkyl and wherein said heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylalkyl, and carbocyclylalkyl are each optionally substituted with 1-4 substituents selected from C,_¢ alkyl, C,.¢ alkenyl, C,¢ alkynyl, halo, C.4 haloalkyl, CN, NO, OR”, SR”, CORY, C(O)OR”, C(O)NR“R!, NRIR'S,
NR’CONHR', NR“C(O)R", NR“C(O)OR®, S(O)RY, S(0)}R"™, S(O)NR'“R!® or
SONR“R';
RF is H, OH, Cy alkyl, C;.¢ haloalkyl, C, alkoxy, Ci. haloalkoxy, heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylalkyl, carbocyclylalkyl, SOR, SOR!’ or SO;-
NR'R'%, wherein said Cj alkyl is optionally substituted with 1-5 substituents selected from hydroxyl, OH, Ci. alkoxy, and Cy.¢ haloalkyl and wherein said heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylalkyl, and carbocyclylalkyl are optionally substituted with 1-4 substituents selected from Cp alkyl, Cy alkenyl, Cs. alkynyl, halo, Ci haloalkyl, CN, : NO, OR®, SR¥, CORY, C(O)ORP, C(O)NRPR!, NRURY, NRCONHR'S, NRC(O)RY, NR¥C(0)ORY, S(O)RY, S(O)R", S(O)NR'*R or SO,NR"R';
R! is Cy alkyl, Cy. haloalkyl, (Co.¢ alkyl)-O-(C1s alkyl), (Cos alkyl)-S~(Ci.¢ alkyl), (Cou alkyl)-(Cs.1 cycloalkyD)-(Co alkyl), OH, OR, SR', COR, COR", CONR'R", carbocyclyl, heterocyclyl, CN, NRIR?, NR'SO,RY, NR!YCORY, NR°CO,RY,
NR'’CONR™2, CR"R"'CO,R" or CR™R"'OCORY;
R?, R®, R*, R® and RS are each, independently, H, OH, halo, Cs alkyl, C.¢ haloalkyl,
Cis alkoxy, Cis haloalkoxy, Ci thioalkoxy, NR'R'2, NR'CO;R; NR'®CONR'R",
NR'SO,NR'R'?, NRY-SO»-R!, heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclyloxy, CN, NO,, COR, CONR! RZ, CO,R!, NO,, SR!?, SOR, SO,R"; or SO;-
NRI!°R 12
R’ is H or Cys alkyl optionally substituted by 1-3 substituents selected from halo, OH,
CO:H, CO,-(C,¢ alkyl), or C;_; alkoxy;
R® and R® are each, independently, H, C,.¢ alkyl, halo, C;.; alkoxy, C3 haloalkoxy,
Cs cycloalkyl, Cs. cycloalkyloxy, OH, CO,R'®, OCOR'’; wherein said Ci alkyl is optionally substituted with one or more substituents selected from F, Cj; alkoxy, OH or
CORY or R” and R® together form a bridging C,.q alkylene or (Cy. alkyl)-O-(C,.3 alkyl)- group to form a 5-7 membered ring; or R® and R? together with the carbon atom to which they are attached form a 3-7 membered spirocyclyl group;
R® and RY are each, independently, H, C.¢ alkyl, halo, C.3 alkoxy, Ci.; haloalkoxy,
Cs cycloalkyl, Cig cycloalkyloxy, OH, COR, OCOR!® , wherein said Cj. alkyl is optionally substituted with one or more substituents selected from F, C,.; alkoxy, OH or
CORY, or R® and R® together with the carbon atom to which they are attached form a 3-7 membered spirocyclyl group; or R® and R? together with the C atoms to which they are attached form a fused 3-7 membered cycloalkyl group or 3-7 membered heterocycloalkyl group;
RY is H, Cj.salkyl, benzyl, phenyl, or Css cycloalkyl, wherein said Ci alkyl, benzyl, phenyl, or Cs cycloalkyl is optionally substituted with 1-3 selected from halo, OH, Cis alkyl, C,.3 haloalkyl, C.3 alkoxy, Ci.3 haloalkoxy, COH, and CO,~(C, alkyl);
R!! is H, OH, Cy alkyl, C, alkoxy, benzyl, phenyl, benzyloxy, phenyloxy, Cs. cycloalkyl or Css cycloalkyloxy, wherein said Cis alkyl, Cis alkoxy, benzyl, phenyl, benzyloxy, phenyloxy, Cs.¢ cycloalkyl or Cs. cycloalkyloxy, is optionally substituted with 1- 3 substituents selected from halo, OH, Cy; alkyl, C1.; alkoxy, CO;H, CO,-(C1 alkyl) and
CFs;
R'? is H, C,¢alkyl, benzyl, phenyl, or Cs. cycloalkyl, wherein said Cy. alkyl, benzyl, phenyl, or Ci cycloalkyl is optionally substituted with 1-3 selected from halo, OH, Ci. alkyl, C,.3 haloalkyl, Cy; alkoxy, C.3 haloalkoxy, CO.H, and CO,-(C). alkyl);
R" and R! are each, independently, H, Cy alkyl, Ci haloalkyl, Ca alkenyl, Ca. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl;
RY and R'S are each, independently H, Ci alkyl, Ci haloalkyl, C, alkenyl, Ci. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R" and R'S together with the N atom to which they are attached form a 4-6 membered heterocyclyl group; pisOor 1; and with the proviso that wherein A is O and one of R® and RY is H, the other of R® and
R¥ is other than Cy.3 alkoxy, C,.3 haloalkoxy, Cs.¢ cycloalkyloxy or OH.
In some embodiments, W is
RA
() (95 ww,
In some embodiments, W is
RS he \|/
RBT
In some embodiments, V is CR’.
In some embodiments, X is CR2.
In some embodiments, Y is CR.
In some embodiments, Z is CR.
In some embodiments, X is N.
In some embodiments, Z is N.
In some embodiments, both X and Z are N.
In some embodiments, X is CR? Y is CR®; and Z is CR".
In some embodiments, V is CR’ X is CR: Yis CR} and Z is CRY.
In some embodiments, no more than 2 of V, X, Y, and Z are N.
In some embodiments, at least 2 of V, X, Y, and Z are other than N or NO.
In some embodiments, none of V, X, Y, and Z are N or NO.
In some embodiments, 1 of V, X, Y,and Z is N.
In some embodiments, 2 of V, X, Y, and Z are N.
In some embodiments, A is O.
In some embodiments, A is CR°RP.
In some embodiments, A is CR°R®, one of RE and RP is OH or Ci alkoxy and the other of RE and RP is heterocyclyl or carbocyclyl wherein said heterocyclyl or carboeyclyl is optionally substituted with 1-4 substituents selected from C4 alkyl, Cz alkenyl, Cas alkynyl, halo, C14 haloalkyl, CN, NO,, OR”, SR”, C(O)R", C(O)OR", C(O)NR"R",
NRIRY, NRISCONHR'S, NR¥*C(O)R™, NR*C(0)ORY, S(O)R™, S(O%R™, S(O)NRR" or SONRVR'Y.
In some embodiments, R®, R*!, RBand RP! are each, independently, H, OH, halo, Ci. alkyl, C,. alkenyl, Cy. alkynyl, C, haloalkyl, Cy alkoxy or Ci. haloalkoxy.
In some embodiments, R®, R*, RPand RP! are each, independently, H, OH or Ci. alkoxy.
In some embodiments, R®, R*!, RBand RB! are each, independently, H or OH.
In some embodiments, RA, R*!, RBand RB! are each H.
In some embodiments, R! is Cy.¢ alkyl, C;.¢ hydroxyalkyl, -(Co.¢ alkyl)-O~(Cy.¢ alkyl), or heterocyclyl (e.g., a 3-7 membered heterocycloalkyl group such as tetrahydrofuanyl).
In some embodiments, R® is (Co. alkyl)-O-(C,.4 alkyl).
In some embodiments, R! is Ci. alkyl.
In some embodiments, R' is prop-2-yl.
In some embodiments, one of R® and R® is other than H.
In some embodiments, one of R® and R® is C14 haloalkyl.
In some embodiments, R® is Ci haloalkyl.
In some embodiments, R® is CFs.
In some embodiments, R” is H.
In some embodiments, one of R® and RY is H and the other is Ci.galkyl, Ci.salkyl or halo.
In some embodiments, one of R® and RY is H and the other is Ci.¢ alkyl.
Tn some embodiments, one of R® and R¥ is H and the other is methy! or cthyl.
In some embodiments, R® and RY are both H.
In some embodiments, p is 0.
In some embodiments, p is 1.
In some embodiments, compounds of the invention have Formula Ja: rR’ 0 A
R® | AR
RE baa Le R®
RY A ( 5m I T
YT ORS
Ia.
In some embodiments, compounds of the invention have Formula Ib, Ic or Id: 7 0)
Re . RE N RT N RA 9
R ( 5 JZ. RO
RY A Xe I
YRS
Ib ’ R7 le] (RS
Re CF)
R® ( JZ. _R®
RY A SE T
Y7 ORS
Ic
Rr’ 0
RE
R® N gt N
R® Z. RE
RY A X. 1
YT TRS
Id.
In some embodiments, compounds of the invention have Formula Ie or If:
Rr’ 0)
R® \ PN RB
RE N R N A
R® Ln 2 RE 7 SE
Xa
Y~ RS
Ie
R7 Q
RE ef SCR
R® LUN 2 RS
RY A T
Xs
Y RS
If.
In some embodiments, compounds of the invention have Formula Ig:
F3 0 1 - ] . .R8 H 5 0]
Ig.
In some embodiments, compounds of the invention have Formula Ih or Ii: 0) , RB
RE R® H NY N
O R'{, N__z CF eh (@) RB1 X. =
TY
Ih 0 1 RA rey or 1 '
RV, Az crs ), RA1 J
Xv?
I.
At various places in the present specification, substituents of compounds of the invention are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges.
For example, the term “Cy.¢ alkyl” is specifically intended to individually disclose methyl, ethyl, C3 alkyl, C, alkyl, Cs alkyl, and Cs alkyl.
For compounds of the invention in which a variable appears more than once, each variable can be a different moiety selected from the Markush group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound; the two R groups can represent different moieties selected from the
Markush group defined for R.
It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
As used herein, the term “alkyl” is meant to refer to a saturated hydrocarbon group which is straight-chained or branched. Example alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g., n- pentyl, isopentyl, neopentyl), and the like. An alkyl group can contain from 1 to about 20, from 2 to about 20, from 1 to about 10, from 1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3 carbon atoms.
As used herein, “alkylene” refers to a divalent alkyl group.
As used herein, “Cy4 alkylene” refers to alkylene groups comprised of from 2 to 4 carbon atoms.
As used herein, “alkenyl” refers to an alkyl group having one or more double carbon- carbon bonds. Example alkenyl groups include ethenyl, propenyl, cyclohexenyl, and the like.
As used herein, “alkynyl” refers to an alkyl group having one or more triple carbon- carbon bonds. Example alkynyl groups include ethynyl, propynyl, and the like.
As used herein, “haloalkyl” refers to an alkyl group having one or more halogen substituents. Example haloalkyl groups include CFs, CFs, CHF;, CCl3, CHCl,, CCl, and the like.
As used herein, “aryl” refers to monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbons such as, for example, phenyl, naphthyl, anthracenyl,
phenanthrenyl, indanyl, indenyl, and the like. In some embodiments, aryl groups have from 6 to about 20 carbon atoms.
As used herein, “carbocyclyl” groups are saturated (i.e., containing no double or triple bonds) or unsaturated (i.¢., containing one or more double or triple bonds) cyclic hydrocarbon moieties. Carbocyclyl groups can be mono- , poly- (e.g., 2, 3 or 4 fused rings) or spirocyclic.
Example carbocyclyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, 1,3-cyclopentadienyl, cyclohexenyl, norbornyl, norpinyl, norcarnyl, adamantyl, phenyl, and the like. Carbocyclyl groups can be aromatic (e.g., “aryl”) or non-aromatic (e.g., “cycloalkyl”). In some embodiments, carbocyclyl groups can have from about 3 to about 30 carbon atoms, about 3 to about 20, about 3 to about 10, or about 3 to about 7 ring-forming carbon atoms.
As used herein, “cycloalkyl” refers to non-aromatic carbocycles including cyclized alkyl, alkenyl, and alkynyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems as well as spiro ring systems. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of pentane, pentene, hexane, and the like. In some embodiments, cycloalkyl groups can have from about 3 to about 10, about 3 to about 10, or about 3 to about 7 ring- forming carbon atoms. In some embodiments, the cycloalkyl group can have 0, 1, 2,3, 4 or 5 double or triple bonds. In yet further embodiments, one or more ring-formaing carbon atoms of a cycloalkyl group can be substituted by an oxo or sulfido group.
As used herein, “heterocyclyl” or “heterocycle” refers to a saturated or unsaturated cyclic hydrocarbon wherein one or more of the ring-forming carbon atoms of the cyclic hydrocarbon is replaced by a heteroatom such as O, S, or N. Heterocyclyl groups can be aromatic (e.g., “heteroaryl”) or non-aromatic (e.g., “heterocycloalkyl™). Heterocyclyl groups can also correspond to hydrogenated and partially hydrogenated heteroaryl groups.
Heterocyclyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems. Heterocyclyl groups can be characterized as having 3-14 or 3-7 ring-forming atoms.
In some embodiments, heterocyclyl groups can contain, in addition to at least one heteroatom, from about 1 to about 13, about 2 to about 10, or about 2 to about 7 carbon atoms and can be attached through a carbon atom or heteroatom. In further embodiments, any ring- forming carbon or heteroatom can be oxidized (e.g., have an oxo or sulfido substituent) or a nitrogen atom can be quaternized. Examples of heterocyclyl groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo-1,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like, as well as any of the groups listed below for “heteroaryl” and “heterocycloalkyl.” Further example heterocycles include pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, 3,6- dihydropyridyl, 1,2,3,6-tetrahydropyridyl, 1,2,5,6-tetrahydropyridyl, piperidonyl, 4- piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thia-diazinyl, [,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3- triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, xanthenyl, octahydro-isoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzo- thiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, deca-hydroquinolinyl, 2H,6H-1,5,2dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl and isoxazolyl. Further examples of heterocycles include azetidin- 1-yl, 2,5-dihydro-1H-pyrrol-1-yl, piperindin-1yl, piperazin-1-yl, pyrrolidin-1-yl, isoquinol-2- yl, pyridin-1-yl, 3,6-dihydropyridin-1-yl, 2,3-dihydroindol-1-yl, 1,3,4,9-tetrahydrocarbolin-2- yl, thieno[2,3-c]pyridin-6-yl, 3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-yl, 1,2,4,4a,5,6-hexahydro-pyrazino[1,2-a]quinolin-3-yl, pyrazino[1,2-a]quinolin-3-yl, diazepan- 1-yl, 1,4,5,6-tetrahydro-2H-benzo[flisoquinolin-3-yl, 1,4,4a,5,6,10b-hexahydro-2H- benzo[f]isoquinolin-3-yl, 3,3a,8,8a-tetrahydro-1H-2-aza-cyclopenta[a]inden-2-yl, and 2,3,4,7-tetrahydro-1H-azepin-1-yl, azepan-1-yl.
As used herein, “heteroaryl” groups refer to an aromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Examples of heteroaryl groups include without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl (furanyl), quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like. In some embodiments, the heteroaryl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heteroaryl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heteroaryl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms.
As used herein, “heterocycloalkyl” refers to non-aromatic heterocycles including cyclized alkyl, alkenyl, and alkynyl groups where one or more of the ring-forming carbon atoms is replaced by a heteroatom such as an O, N, or S atom. Example “heterocycloalkyl” groups include morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, 2,3-dihydrobenzofuryl, 1,3-benzodioxole, benzo-1,4-dioxane, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, and the like. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the nonaromatic heterocyclic ring, for example phthalimidyl, naphthalimidyl, and benzo derivatives of heterocycles such as indolene and isoindolene groups. In some embodiments, the heterocycloalkyl group has from 1 to about 20 carbon atoms, and in further embodiments from about 3 to about 20 carbon atoms. In some embodiments, the heterocycloalkyl group contains 3 to about 14, 3 to about 7, or 5 to 6 ring-forming atoms. In some embodiments, the heterocycloalkyl group has 1 to about 4, 1 to about 3, or 1 to 2 heteroatoms. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double or triple bonds.
As used herein, “spirocyclyl” refers to a 3-14 membered cycloalkyl or 3-14 membered heterocycloalkyl group sharing one atom with a further cycloalkyl or heterocycloalkyl group to which it is attached.
As used herein, “halo” or “halogen” includes fluoro, chloro, bromo, and iodo.
As used herein, “alkoxy” refers to an -O-alkyl group. Example alkoxy groups include methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), t-butoxy, and the like.
As used herein, “thioalkoxy” refers to an —S-alkyl group.
As used herein, “haloalkoxy” refers to an —O-haloalkyl group. An example haloalkoxy group is OCF. :
As used herein, “carbocyclyloxy” refers to —O-carbocyclyl.
As used herein, “cycloalkyloxy” refers to —~O-cycloalkyl.
S As used herein, “carbocyclylalkyl” refers to alkyl substituted by carbocyclyl.
As used herein, “aralkyl” or “arylalkyl” refers to an alkyl group substituted by an aryl group.
As used herein, “cycloalkylalkyl” refers to an alkyl group substituted by an cycloalkyl group.
As used herein, “heterocyclylalkyl” refers to an alkyl moiety substituted by a heterocarbocyclyl group. Example heterocyclylalkyl groups include “heteroarylalkyl” (alkyl substituted by heteroaryl) and “heterocycloalkylalkyl” (alkyl substituted by heterocycloalkyl). In some embodiments, heterocyclylalkyl groups have from 3 to 24 carbon atoms in addition to at least one ring-forming heteroatom.
As used herein “oxo” refers to =O.
The compounds described herein can be asymmetric (e.g., having one or more stercocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms.
Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallizaion using a “chiral resolving acid” which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as B-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms,
or diastercomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N- methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.
Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
Compounds of the invention also include tautomeric forms, such as keto-enol tautomers.
Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and : deuterium. :
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The present invention also includes pharmaccutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed.,
Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical
Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
The present invention also includes prodrugs of the compounds described herein. As used herein, “prodrugs” refer to any covalently bonded carriers which release the active parent drug when administered to a mammalian subject. Prodrugs can be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds wherein hydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, sulfhydryl, or carboxyl group respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups inthe compounds of the invention. Preparation and use of prodrugs is discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium
Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American
Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference in their entirety.
Synthesis
Compounds of the invention, including salts, hydrates, and solvates thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.
The reactions for preparing compounds of the invention can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.
Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art.
The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M.
Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999), which is incorporated herein by reference in its entirety.
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.8., 'H or PC) infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.
Examplary synthetic routes to compounds of the invention are provided in Schemes 1- 13 below, where constituent members of the depicted formulae are defined herein. 3-Aminopentanecarboxylic acids of formula 1-5 can be prepared using the protocol described in Scheme 1. The commercially available carboxylic acid 1-1 can be converted to an ester such as a methyl ester by treatment with jodomethane/potassium carbonate in DMF.
The resulting ester 1-2 can be subjected to an alkylation with a halide such as an iodide (R'T) using a base such as lithium hexamethyldisilazide (LHMDS) to provide the alkylated product 1-3 as a mixture of cis and trans diastereomers (4:1 ratio). The minor trans diastereomer can be removed by crystallization following hydrolysis of the ester to an acid. The resulting enantiopure acid 1-4 can be subjected to a hydrogenation using a catalyst such as Pd-C to afford the saturated carboxylic acid 1-5.
Scheme 1 0 0]
Mel/K,CO: LHMDS/THF soc 0" TR, soni “ome Bikintiebble i
DMF RY
1-1 1-2 0 o}
LiOH/MeOH
H,/Pd-C/EtOH
BocHN OMe ——4M8 ——» 7 oH TEER oc ea THF/H,0 en 1-3 14 0 sec Fo OH
R
1-5
Cyclopentanecarboxylic acids of formula 2-5 can be prepared using the procedures outlined in Scheme 2. The commercially available 3-oxocyclopentanecarboxylic acid 2-1 can be converted to an ester such as methyl ester. The ketone of the resulting ester 2-2 can be protected by treatment with trimethyl orthoformate in the presence of an acidic catlyst such as paratoluenesulfonic acid. Alkylation of the resulting ketal 2-3 with an alkyl iodide R'T) can be accomplished using a base such as LHMDS. Hydrolysis of the alkylated ester 2-4 using a base such as LiOH, NaOH or KOH provides the carboxylic acids of formula 2-5.
Scheme 2 0] 0
Mel/K,CO oT op _MevkeCOs o=(Y ome TMOF/pTSA
DMF
2-1 2-2
Oo O q LHMDS/THF nd OH" 0] OMe — _— > o OMe — > / RY / R! 2-3 2-4
Oo q OH
A R
2-5
Piperazine derivatives can be prepared using the procedures depicted in Scheme 3.
Coupling of a piperazine derivative of formula 3-2 with an iodobenzene derivative of formula 3-1 using copper(I) iodide and potassium phosphate gives rise to the intermediate 3-3.
Removal of the Boc group using an acid such as HCl in dioxane or TFA provides the piperazine derivatives of formula 3-4.
Scheme 3
B RB1
RE A RB
RE BocN NH 30 BocNT A RS . \_/ 3 L 6 H —_—— _-N RP ——
R2 RS Cul/K3POy4 RE?
R3 R2 R® 3-1 33 FR
RB
HN" 3 R4 6 aN R
R? RS 34 R
Alternatively, piperazine derivatives (formula 4-3) can be prepared by displacement of a 2-chloropyridine or 2-chloropyrimidine derivative of formula 4-1 with a piperazine derivative of formula 4-2.
Scheme 4
RE RBt RB
NA HN
CZs R® HN NH 42 L, N__z_ RS
I RBI hi ~N
ZZ R5 TEA/DMF Nps
R3 R3 4-1 4-3
Alternatively, piperazine derivatives can be prepared using a sequence as illustrated in
Scheme 5. The commercially available 3,5-dibromopyridine 5-1 can be converted to 3- bromo-5-iodopyridine 5-2 by treatment with isopropylmagnesium bromide and iodine.
Coupling of the resulting iodo with a piperazine derivative of formula 3-2 can be accomplished using copper(I) iodide and potassium phosphate. Following conversion of the bromo of the resulting intermediate 5-3 to iodo using isopropylmagnesium bromide and iodine, the iodo can be displaced with trifluoromethyl by treatment with
Me;SiCF3/Cul/KF/DMF to afford the trifluoromethylpyridine derivative of formula 5-5.
Removal of the Boc using an acid such as HCI in dioxane or TFA yields the piperazine derivatives of formula 5-6.
Scheme §
B RB! a
Br Br BocN NH 3-2 xn i-PrMgBr/l, | x Br \ )
Tr J Cul/K3PO
N N 3 4 5-1 5-2
B
RB _~R ~~ 7
Bo” 7) o, rpigam, 2° CY | MesSICFs , Ls € _—
RET Tr RM! Df CUl/KF/DMF 2 2
N N
6-3 5-4
RB R®
Boh”) wo WA rei | Nn CF3 — a p U7 55 N 56 N
Piperidine or tetrahydropyridine derivatives can be synthesized as shown in Scheme 6. Lithiation of a bromo- or iodobenzene derivative of formula 6-1 with an alkyllithium such as n-butyllithium or fert-butyllithium followed by quenching with a ketone derivative of formula 6-2 provides the tertiary alcohol of formula 6-3. Following dehydration using a dehydrating agent such as thionyl chloride/pyridine, the resulting olefin 6-4 can be reduced by hydrogenation using a catalyst such as Pd on carbon. Treatment of 6-3, 6-4 and 6-5 with an acid such as HCl in dioxane or TFA provides compounds of formulae 6-6, 6-7 and 6-8.
Scheme 6
Al
R4 RAR RA 6 / BocN”N oH R*
X R® BocN 0 62 L o s SOCL/Py oN a AF R®
R2 RS ~~ BuLUTHF R
R3 Rr? RS 6-1 6-3 R
X=Br, | AN
RA RA RA
Boh) RY - Li OR HN OH RA 6 6 6
A R > RAT R RAT R
R? RS Rr? R® R? RS 64 R3 67 RS 66 RS?
Ho/PA-C
RA RA
Boo R¢ i» HN ~N RS 6 6
RAT RW — RAT R
R2 RS R2 RS 65 R 68 R°
Alternatively, piperidine or tetrahydropyridine derivatives can be synthesized as illustrated in Scheme 7. A commercially available 2-chloropyridine or 2-chloropyrilidine derivative of formula 4-1 can be converted to 2-bromopyridine derivative of formula 7-1 by treatment with BrSiMes. Using similar procedures described in Scheme 6, piperidine and tetrahydropyridine derivatives of formula 7-5 and 7-6 can be obtained from 7-1.
Claims (57)
1. A compound of Formula I: x R7 o z°° Vv i” R8 Cr
RO. I or pharmaceutically acceptable salt or prodrug thereof, wherein: a dashed line indicates an optional bond; W is: RA T Q I (7 NM p RM or RB! Vis N, NO or CR% XisN, NO or CRY Y is N, NO or CR’; Z is N, NO or CR*; wherein no more than one of X, Y and Z is NO; Ais O, S, CRR® or NR; RA, RA! RBand R' are each, independently, H, OH, halo, Ci. alkyl, Ci.s alkenyl, Cis alkynyl, C.¢ haloalkyl, Ci. alkoxy, C1.¢ haloalkoxy, heterocyclyl, carbocyclyl, NR'°R", NR'°CO,RY; NR’CONRR"?, NR°SO,NRI°R!2, NRV-SO,-R"!, CN, CONR'R™, COR", NO2, SR!, SOR'?, SO;R"; or SO,-NR'’R"; RC and RP are each, independently, H, OH, halo, C16 alkyl, Cj.¢ haloalkyl, Cj.6 alkoxy, C,. haloalkoxy, C,.¢ thioalkoxy, heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylaikyl, carbocyclylalkyl, NR'*R'2, NR'*COR"; NR'’CONRMRY, NR1°SO,NR'R'?, NR'-80,R"!, CN, CONR'°R"?, COR’, NO,, SR’, SOR", SOR"; or SO,-NR°R'?, wherein said Cy.¢ alkyl is optionally substituted with 1-5 substituents selected from hydroxyl, OH, Cy.¢alkoxy, and Ci.¢ haloalkyl and wherein said heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylalkyl, and carbocyclylalkyl are each optionally substituted with 1-4 substituents selected from Cy. alkyl, Cz alkenyl, Cz. alkynyl, halo, C;.4 haloalkyl, CN, NO,, OR", SRY, C(O)R", C(O)OR", C(O)NRPR'S, NR"RS, NRCONHRS, NRISC(O)RY, NRIC(O)OR?, S(O)R', S(O),R", S(O)NRVR'® or
SO.NRISR'S,
RF is H, OH, Cis alkyl, Ci haloalkyl, Cy.s alkoxy, Cis haloalkoxy, heterocyclyl, carbocyelyl, carbocyelyloxy, heterocyclylalkyl, carbocyclylalkyl, SOR, SO,R'Y; or SO»- NR!®R', wherein said Cy.¢alkyl is optionally substituted with 1-5 substituents selected from hydroxyl, OH, C, alkoxy, and Cy.6 haloalkyl and wherein said heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclylalkyl, and carbocyclylalkyl are optionally substituted with 1-4 substituents selected from Cy. alkyl, Ca alkenyl, Cz alkynyl, halo, C4 haloalkyl, CN, NO,, OR", SR'?, C(O)R", C(O)OR", C(O)NR"R'S, NRPR', NR'SCONHR'®, NR C(O)R™, NR'*C(O)OR", S(O)R™, S(0),R*, S(O)NRR'® or SO,NR'R'¢; R! is C6 alkyl, Ci haloalkyl, Ci.6 hydroxyalkyl, {Co.s alkyl)-0-(Ci alkyl), (Cos alkyl)-S-(C1.6 alkyl), (Cos alkyl)-(Cs- cycloalkyD-(Co-s alkyl), OH, OR'?, SR'®, COR", CO,R!, CONR'R", carbocycly}, heterocyclyl, CN, NRYR, NR'’SO;R"’, NR'°COR", NRYCO,R'. NRPCONR'2, CRYR!'COR"’ or CR’R''OCOR™"; RZ R®, R%, RS and R® are each, independently, H, OH, halo, Ci alkyl, C16 haloalkyl,
C1. alkoxy, Cr. haloalkoxy, Cy. thicalkoxy, NR'R", NRPCO;R!; NR1CONR'RY, NR!°SO,NRRY, NR°-80,-R!!, heterocyclyl, carbocyclyl, carbocyclyloxy, heterocyclyloxy, CN, NO,, COR", CONR'R"?, CORY, NO, SRY, SOR’, SO;R'; or SO2- NRUR'2 R7 is H or Cy.¢ alkyl optionally substituted by 1-3 substituents selected from halo, OH, COuH, CO,-(Cy.g alkyl), or Cy alkoxy; R® and R® are each, independently, H, Cy. alkyl, Cy.¢ haloalkyl, halo, Ci.3 alkoxy, Ci. , haloatkoxy, Cs. cycloalkyl, Cs. cycloalkyloxy, OH, CORY, OCOR!?; wherein said Ci-6 alkyl is optionally substituted with one or more substituents selected from F, C3 alkoxy, OH or CORY; or R7 and R? together form a bridging C4 alkylene or —(Cq2 alkyl)-O-(C\.3 alkyl)- group to form a 5-7 membered ring; or R® and R¥ together with the carbon atom to which they are attached form a 3-7 membered spirocyclyl group; R®and RY are each, independently, H, Cy. alkyl, halo, Cy.3 alkoxy, Ci.3 haloalkoxy,
Cs. cycloalkyl, Cs.¢ cycloalkyloxy, OH, CO,R'°, OCOR!®, wherein said C,.¢ alkyl is optionally substituted with one or more substituents selected from F, C;.3 alkoxy, OH or CO,R'?: or R® and R” together with the carbon atom to which they are attached form a 3-7 membered spirocyclyl group;
or R® and R? together with the C atoms to which they are attached form a fused 3-7 membered cycloalkyl group or 3-7 membered heterocycloalkyl group; R'is H, Cy.¢ alkyl, benzyl, phenyl, or Cs.6 cycloalkyl, wherein said Cis alkyl, benzyl, phenyl, or C3 cycloalkyl is optionally substituted with 1-3 selected from halo, OH, Cy.3 alkyl, Cy.3 haloalkyl, Cy.3 alkoxy, C13 haloalkoxy, CO;H, and CO2~(Cy.6 alkyl); R! is H, OH, Cy.s alkyl, Cys alkoxy, benzyl, phenyl, benzyloxy, phenyloxy, Ci. cycloalkyl or Cs. cycloalkyloxy, wherein said C1. alkyl, C16 alkoxy, benzyl, phenyl, benzyloxy, phenyloxy, Cs. cycloalkyl or Cs.6 cycloalkyloxy, is optionally substituted with 1- 3 substituents selected from halo, OH, Ci.3 alkyl, C,.; alkoxy, CO2H, CO,-(C.¢ alkyl) and CFs; R'is H, C4 alkyl, benzyl, phenyl, or C3.¢ cycloalkyl, wherein said Ci.¢ alkyl, benzyl, phenyl, or C34 cycloalkyl is optionally substituted with 1-3 selected from halo, OH, Ci.3 alkyl, Ci.3 haloalkyl, Cy.; alkoxy, C.3 haloalkoxy, CO.H, and CO,-(Cys alkyl); R'3 and R are each, independently, H, Cy alkyl, Ci. haloalkyl, C;.6 alkenyl, Ca. alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; R!S and R are each, independently H, Ci alkyl, Cy. haloalkyl, Ca.6 alkenyl, Ca.6 alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl; or R' and R'® together with the N atom to which they are attached form a 4-6 membered heterocyclyl group; pisOorl;and with the proviso that when A is O and one of R® and Ris H, the other of R® and R® is other than C.3 alkoxy, C3 haloalkoxy, Ci. cycloalkyloxy or OH.
2. The compound of claim 1 wherein W is RA i) (55 Re,
3. The compound of claim 1 wherein W is RE SEAN R81
4. The compound of claim 1 wherein V is CRS.
S. The compound of claim 1 wherein X is CR.
6. The compound of claim 1 wherein Y is CR’.
7. The compound of claim 1 wherein Z is CR.
8. The compound of claim 1 wherein X is CR% Y is CR? and Z is CR".
9. The compound of claim 1 wherein V is CR?, X is CR* Y is CR} and Zis CRY.
10. The compound of claim 1 wherein A is O.
11. The compound of claim 1 wherein A is CRRP.
12. The compound of claim 1 wherein A is CR®RP, one of RE and RP is OH or Cy. alkoxy and the other of RC and RP is heterocyclyl or carbocyclyl wherein said heterocyclyl or carbocyclyl is optionally substituted with 1-4 substituents selected from C).¢ alkyl, Ca alkenyl, C5 alkynyl, halo, C14 haloalkyl, CN, NO, OR", SRB, C(O)R™, C(O)ORY, C(O)NRPR'S, NRR'S, NR *CONHR', NRYC(O)R!, NRPC(O)ORY, S(O)R™, S(O)RY, S(O)NRPR' or SO,NRR".
13. The compound of claim 1 wherein RA, RM, RBand RB! are each, independently, H, OH, halo, Cy¢alkyl, Cysalkenyl, Cy. alkynyl, C1.¢ haloalkyl, Cy.¢ alkoxy or Cy. haloalkoxy,.
14. The compound of claim 1 wherein RA, RAL RBand RB! are each, independently, H, OH or C,.¢ alkoxy.
15. The compound of claim 1 wherein R” RA! RPand RP! are each, independently, H or
OH.
16. The compound of claim 1 wherein R' is Cy. alkyl, C1. hydroxyalkyl, -(Cos alkyl)-O- (C6 alkyl), or heterocyclyl.
17. The compound of claim 1 wherein R'is Cy. alkyl.
18. The compound of claim 1 wherein R! is prop-2-y1.
19. The compound of claim 1 wherein one of R® and R® is other than H.
20. The compound of claim 1 wherein one of R® and R® is C4 haloalkyl.
21. The compound of claim 1 wherein R® is C14 haloalkyl.
22. The compound of claim 1 wherein R® is CF.
23. The compound of claim 1 wherein R’isH.
24. The compound of claim 1 wherein one of R® and RY is H and the other is Cy.¢ alkyl,
C1. alkyl or halo.
25. The compound of claim 1 wherein one of R® and RY is H and the other is Cr.¢ alkyl.
26. The compound of claim 1 wherein one of R® and R¥ is H and the other is methyl or ethyl.
27. The compound of claim 1 wherein R® and R? are both H.
28. The compound of claim 1 having Formula la: R7 0 Re \ RA R° Yo Le RE RY A 3» I I *Y7 ORS
Ia.
29. The compound of claim 1 having Formula Ib, Ic or Id:
R7 Q Re R® ZR 9 P ~ RA Xe YRS Ib R7 2 RS \ RS zZ._R® 9" P ~ R®Y A Xs YY” "RS Ic R7 0 Re RS N R1 N 9 6 RS “1 R¥" A Xey "Spe
1d.
30. The compound of claim 1 having Formula Ie or If: RY (¢] Rr? Oo aR 4 AE g 3 R RI 3 R rt NY R® ANZ. RE R (UN _Z._RS Ao ET WA TX YRS YOUR le If.
31. The compound of claim 1 having the Formula Ig: CF3 0 je J 8 H a oleh 10]
Ig.
32. The compound of claim 1 having the Formula Ih or Li:
[0] r8 R® ora) 3 R! SNES CFs 0 RE! J : Th 'S! R' LI z,_ CFs ° “1S Y
Ii.
33. The compound of claim 1 which is selected from: N-[(1R,35)-3-Isopropyl-3-9 {4-[3-(trifluoromethyl)phenyl]piperazin- 1- yl} carbonyl)cyclopentyljtetrahydro-2H-pyran-4-amine; N-[(1R,35)-3-Isopropyl-3-({4-[4-(trifluoromethyl)phenyl]piperazin-1- yh} carbonyl)cyclopentyltetrahydro-2H-pyran-4-amine; N-[(1R,3S)-3 _Isopropyl-3-({4-[2-(trifluoromethyl)phenyl]piperazin-1- yl}carbonyl)cyclopenty!]tetrahydro-2H-pyran-4-amine; N-[(1R,38)-3-({4-[3 _5-Bis(trifluoromethyl)phenyl]piperazin-1 -yl}carbonyl)-3- isopropylcyclopentyl}tetrabydro-2H-pyran-4-amine ; N-{(1R,3S)-3-1sopropyl-3-({ 4-[3-(trifluoromethy!)phenylipiperazin- 1- yl} carbonyl)cyclopentyl]-3 -methyltetrahydro-2H-pyran-4-amine; 3-Ethyl-N-[( 1R,3S)-3-isopropyl-3-({4-[3-(trifluoromethyl)phenyl]piperazin-1- yl} carbonyl)cyclopentyl]tetrahydro-2H-pyran-4-amine; N-[(1R,3S)-3-Isopropyl-3-({4-[3 ~(triflucromethyl)phenyl]piperazin-1- yl} carbonyl)cyclopentyl]-3-(methoxymethyl)tetrahydro-2H-pyran-4-amine; N-[(1R,38)-3-Isopropyl-3-({4-[4-(trifluoromethyl)pyridine-2-yl]piperazin-1- yl} carbonyl)cyclopentyl]-3-methyltetrahydro-2H-pyran-4-amine; 3-Ethyl-N-[(1R,35)-3-isopropyl-3-({4-[4-(irifluoromethyl)pyridin-2-yl]piperazin-1- yl}carbonyl)cyclopentyltetrahydro-2H-pyran-4-amine; N-[(1R.38)-3-Isopropyl-3-({4-[5-(trifluoromethyl)pyridin-3-yl]piperazin-1- yl}carbonyl)cyclopentyl]-3-methyltetrahydro-2H-pyran-4-amine; 3-Ethyl-N-[(1R,35)-3-isopropy}-3-({4-{5-(trifluoromethyl)pyridin-3-yl]piperazin-1- yl}carbonyl)cyclopentylltetrahydro-2H-pyran-4-amine;
N-{(1 R,3S)-3-Isopropyl-3-[(4-phenyl-3 ,6-dihydropyridin-1(2H)- yl)carbonyl]cyclopentyl} tetrahydro-2H-pyran-4-amine; N-{(1R.35)-3 -Isopropyl-3-[(4-phenyl-3 ,6-dihydropyridin-1(2H)- yl)carbonyl]cyclopentyl} -3-methyltetrahydro-2H-pyran-4-amine; N-{(1R,35)-3 -Isopropyl-3-[(4-phenylpiperidin- 1 -yl)carbonyl]cyclopentyl}tetrahydro- 2H-pyran-4-amine; 1-{((1S,3R)-1-Isopropyl-3- { [3-methyltetrahydro-2H-pyran-4- ylJamino} cyclopentylcarbonyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-ol; 1-[((1S,3R)-1-Tsopropyl-3-{[3 -methyltetrahydro-2H-pyran-4- ylJamino} cyclopentyl) arbonyl]-4-[4-(triflucromethyl)phenyl] piperidin-4-ol; N-((1R,38)-3-1sopropyl-3-{[4- [2-(trifluoromethyl)phenyl}-3 ,6-dihydropyridin-1(2H)- yl]carbonyl} cyelopentyl)tetrahydro-2H-pyran-4-amine; N-((1R,38)-3-Isopropyl-3-{[4-[3 ~(trifluoromethyl)phenyl} -3,6-dihydropyridin-1(2H)- yljcarbonyl} cyclopentyl)tetrahydro -2H-pyran-4-amine; N-((1R,38)-3-Isopropyl-3-{[4-[3 -(triftuoromethyl)phenyl] -3,6-dihydropyridin-1(2H)~ ylJcarbonyl}cyclopentyl)-3-methyltetrahydro -2H-pyran-4-amine; 3-Ethyl-N-((1R,38)-3-isopropyl-3-{[4- [3-(trifluoromethyl)phenyl]-3,6- dihydropyridin-1(2H)-yl] carbonyl }eyclopentyl)tetrahydro-2H-pyran-4-amine; N-((1R,38)-3-Isopropyl-3-{ [4-(triflucromethyl)-3 ' 6'-dihydro-2,4'-bipyridin-1'(2'H)- yl]carbonyl} cyclopentyl)-3-methyltetrahydro-2H-pyran-4-amine; 3-Ethyl-N-((1R,3S)-3-isopropyl-3-{ [4-(trifluoromethyl)-3 ' 6'-dihydro-2,4'-bipyridin- 1'(2'H)-yl]carbonyl} cyclopentyl)tetrahydro-2H-pyran-4-amine; N-((1R,38)-3-Isopropyl-3-{ [5-(trifluoromethyl)-3 ' 6'-dihydro-3,4'-bipyridin-1'(2'H)- yl]carbonyl} cyclopentyl)-3-methyltetrahydro-2H-pyran-4-amine ; 3-Ethyl-N-((1R,3S)-3-Isopropyl-3-{ [5-(trifluoromethyl)-3",6'-dihydro-3,4'-bipyridin- 1'(2'H)-yl]carbonyl} cyclopentyl)tetrahydro-2H-pyran-4-amine; N-[(1R,3S)-3-Isopropyl-3 -({4-[4~(trifluoromethyl)pyrimidin-2-yl] piperazin-1- yl} carbonyl)cyclopentyl]-3-methyltetrahydro -2H-pyran-4-amine; and 3-Ethyl-N-[(1R,35)-3-isopropyl-3-({4- [4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1- yl} carbonyl)cyclopentyl]tetrahydro-2H-pyran-4-amine ; N-[(1R,3S)-3-isopropyl-3 ~(4-[6-(trifluoromethyl)pyridin-2-yl]piperazin-1- ylcarbonyl)cyclopentyl]-3 -methyltetrahydro-2H-pyran-4-amine;
N-[(1R,3S)-3-isopropyl-3-(4- [6-(trifluoromethyl)pyrimidin-4-yl]piperazin- 1- ylcarbonyl)cyclopentyl]-3 -methyltetrahydro-2H-pyran-4-amine; N- [(LR35)-3-isopropyl-3-(4-[6-methyl-4-(trifluoromethyDpyridin-2-yllpiperazin-] - ylearbonyl)eyclopentyl]-3-methyltetrahydro-2H-pyran-4-amine; N-[(1R,3S)-3-isopropyl-3-(4-{3 ~(trifluoromethyl)phenyl]piperidin- 1- ylcarbonyl)cyclopentyljtetrahydro-2H-pyran-4-amine; N-[(1R,3S)-3-isopropyl-3-(4-[3 (trifluoromethyl)phenyl}piperidin-1 - ylc arbonyl)cyclopentyl]-3-methyltetrahydro-2H-pyran-4-amine; 2-[(1R,35)-3 -[(3-methyltetrahydro-2H-pyran-4-yl)amino} -1-(4-[4- (trifluoromethyl)pyridin-2-yl}piperazin- 1 -ylcarbonyl)cyclopentyl]jpropan-2-ol; 2-[(1R,35)-3-[(4R)-3 -methyltetrahydro-2H-pyran-4-yljamino-1 -(4-14- (trifluoromethyl)pyrimidin-2-yljpiperazin-1 _ylcarbonyl)cyclopentyl]propan-2-ol; 2-[(18,35)-3-{(3 -methyltetrahydro-2H-pyran-4-yl)amino]-1 -(4-[6- (trifluoromethyl)pyridin-2-yl]pi perazin-1 -ylcarbonyl)cyclopentyl) propan-2-ol; N-[(18,35)-3-ethyl-3 -(4-[4-(trifluoromethyl)pyridin-2-yl]piperazin- 1- ylcarbonyl)cyclopentyl]-3 -methyltetrahydro-2H-pyran-4-amine; (4R)-N-[(1R,35)-3-ethyl-3 -(4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1 - ylcarbonyl)cyclopentyl]-3 -methyltetrahydro-2H-pyran-4-amine; N-[(1 $,35)-3-ethyl-3-(4-[6-(trifluoromethyl)pyridin-2-ylJpiperazin-1 - ylcarbonyl)cyclopentyl}-3 -methyltetrahydro-2H-pyran-4-amine; (4R)-N-[(1R,3S)-3-methyl-3-(4- [4-(trifluoromethyl)pyrimidin-2-yl] piperazin-1- ylcarbonyl)cyclopentyl]-3 -methyltetrahydro-2H-pyran-4-amine; (4R)-3-methyl-N-[(1 R,35)-3-(2-methoxyethyl)-3-(4~ [4-(trifluoromethyl)pyridin-2- ylipiperazin-1 ~ylcarbonyl)cyclopentyl]tetrahydro-2H-pyran-4-amine; 3-methyl-N-[(18,35)-3-(2-methoxyethyl)-3-(4- [4-(trifluoromethyl)pyrimidin-2- yl]piperazin-1 -ylcarbonyl)cyclopenty!]tetrahydro-2H-pyran-4-amine; (4R)-N-[(1R,35)-3-(ethoxymethyl)-3 -(4-[4-(trifluoromethyl)pyridin-2-yl}piperazin-1- ylcarbonyl)cyclopentyl]-3 -methyltetrahydro-2H-pyran-4-amine; (4R)-N-[(1 R,3S)-3-(ethoxymethyl)-3 -(4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1 - ylcarbonyl)cyclopentyl]-3 -ethyltetrahydro-2H-pyran-4-amine; (4R)-N-[(1R,3S)-3-(ethoxymethyl)-3 -(4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin- 1-ylcarbonyl)cyclopentyl}-3 -methyltetrahydro-2H-pyran-4-amine; (4R)-3-methyl-N-[( 1R,38)-3-(methoxymethyl) -3-(4-[4-(trifluoromethyl)pyridin-2- yl]piperazin-1 -ylcarbonyl)cyclopentyl]tetrahydro-2H-pyran-4-amine;
PCT/US2005/022793 (4R)-3-methyl-N-[(1R,35)-3-(methoxymethyl)-3-(4-[4-(trifluoromethyl)pyrimidin-2- yl]piperazin-1-ylcarbonyl)cyclopentyljtetrahydro-2H-pyran-4-amine; (4R)-3-methyl-N-[(1R,35)-3-[(3R)-tetrahydrofuran-3-y1]-3-(4-[4- (trifluoromethyl)pyridine-2-yl]piperazin- 1-ylcarbonyl)cyclopentyl]tetrahydro-2H-pyran-4- amine; and (4R)-3-methyl-N-[(1R,35)-3-[(3R)-tetrahydrofuran-3-yl]-3-(4-[4- (trifluoromethyl)pyrimidin-2-yl]piperazin- 1-ylcarbonyl)cyclopentyl]tetrahydro-2H-pyran-4- amine; or pharmaceutically acceptable salt thereof.
34. A composition comprising a compound of any one of claims 1 to 33 and a pharmaceutically acceptable carrier.
35. A method of modulating activity of a chemokine receptor comprising contacting said chemokine receptor with a compound of any one of claims 1 to 33.
36. The method of claim 35 wherein said chemokine receptor is CCR2.
37. The method of claim 35 wherein said modulating is inhibiting.
38. The method of claim 35 wherein said compound is a selective inhibitor of CCR2.
39. Use of a compound of any one of claims 1 to 33 in the manufacture of a preparation for treating a disease associated with expression or activity of a chemokine receptor in a subject.
40. Use of claim 39 wherein said chemokine receptor is CCR2.
41. Use of claim 39 wherein said compound is a selective inhibitor of CCR2.
42. Use of claim 39 wherein said disease is an inflammatory disease. 122 AMENDED SHEET
PCT/US2005/022793
43, Use of claim 39 wherein said disease is an immune disorder.
44, Use of claim 39 wherein said disease is rheumatoid arthritis, atherosclerosis, lupus, multiple sclerosis, neuropathic pain, transplant rejection, diabetes, or obesity.
45. Use of claim 39 wherein said disease is cancer.
46. Use of claim 45 wherein said cancer is characterized by tumor associated macrophages.
47. Use of claim 45 wherein said cancer is breast cancer, ovarian cancer or multiple myeloma.
48. Use of claim 39 wherein said preparation is administrable together with an anti- inflammatory agent.
49. Use of claim 48 wherein said anti-inflammatory agent is an antibody.
50. Use of a compound of any one of claims 1 to 33 in the manufacture of a preparation for modulating the activity of a chemokine receptor.
51. Use of claim 50 wherein said chemokine receptor is CCR2.
52. Use of claim 50 wherein said modulating is inhibiting.
53. Use of claim 50 wherein said compound is a selective inhibitor of CCR2.
54. A compound according to any one of claims 1 to 33, substantially as herein described with reference to and as illustrated in any of the examples. 123 AMENDED SHEET
PCT/US2005/022793
55. A composition according to claim 34, substantially as herein described with reference to and as illustrated in any of the examples.
56. A method according to any one of claims 35 to 38, substantially as herein described with reference to and as illustrated in any of the examples.
57. Use according to any one of claims 39 to 53, substantially as herein described with reference to and as illustrated in any of the examples. 124 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58348204P | 2004-06-28 | 2004-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200610667B true ZA200610667B (en) | 2008-06-25 |
Family
ID=38126279
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200610426A ZA200610426B (en) | 2004-06-28 | 2006-12-12 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors |
ZA200610667A ZA200610667B (en) | 2004-06-28 | 2006-12-18 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200610426A ZA200610426B (en) | 2004-06-28 | 2006-12-12 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors |
Country Status (4)
Country | Link |
---|---|
CN (2) | CN1976707A (en) |
TN (2) | TNSN06444A1 (en) |
UA (1) | UA83142C2 (en) |
ZA (2) | ZA200610426B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2370442T1 (en) * | 2008-11-26 | 2013-06-28 | Pfizer Inc. | 3-Aminocyclopentanecarboxamides as chemokine receptor modulators |
CN102933579B (en) * | 2009-12-17 | 2015-07-15 | 贝林格尔.英格海姆国际有限公司 | New ccr2 receptor antagonists and uses thereof |
-
2005
- 2005-06-27 UA UAA200613945A patent/UA83142C2/en unknown
- 2005-06-27 CN CN 200580021461 patent/CN1976707A/en active Pending
- 2005-06-27 CN CN 200580021744 patent/CN1976702A/en active Pending
-
2006
- 2006-12-12 ZA ZA200610426A patent/ZA200610426B/en unknown
- 2006-12-18 ZA ZA200610667A patent/ZA200610667B/en unknown
- 2006-12-27 TN TNP2006000444A patent/TNSN06444A1/en unknown
- 2006-12-27 TN TNP2006000443A patent/TNSN06443A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1976707A (en) | 2007-06-06 |
TNSN06444A1 (en) | 2008-02-22 |
UA83142C2 (en) | 2008-06-10 |
TNSN06443A1 (en) | 2008-02-22 |
CN1976702A (en) | 2007-06-06 |
ZA200610426B (en) | 2008-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4116671B2 (en) | 3-Aminocyclopentanecarboxamide as a chemokine receptor modulator | |
CA2571019C (en) | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | |
KR100837019B1 (en) | 3-4-heteroarylcyclohexylaminocyclopentanecarboxamides as modulators of chemokine receptors | |
CA2562235C (en) | Piperazinylpiperidine derivatives as chemokine receptor antagonists | |
US7700624B2 (en) | 3-aminocyclopentanecrboxamides as modulators of chemokine receptors | |
ZA200610667B (en) | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors |